Edward J. Dulac III, Chief Financial Officer at FATE THERAPEUTICS INC (FATE), sold 1,849 shares at $5.00 ($9K) on 2024-01-29, disclosed to the SEC on 2024-01-30.
Scheduled sale ($9k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NTLA | SELL | 2026-01-07 | $59K | — | Filing → |
| NTLA | SELL | 2025-07-25 | $209K | — | Filing → |
| FATE | SELL | 2024-03-05 | $19K | — | Filing → |